Key facts
- This page summarizes James Alexander Cunliffe Foster's Form 3 filing for Virax Biolabs Group Ltd (VRAX).
- 0 reported transactions and 5 derivative rows are listed below.
- Accepted by SEC: 18 Mar 2026, 16:05.
James Alexander Cunliffe Foster - 18 Mar 2026 Form 3 Insider Report for Virax Biolabs Group Ltd (VRAX)
- Reporting relationship
- Chief Executive Officer
- Issuer ticker
- VRAX
- Reported as of
- 18 Mar 2026
- Net transaction value
- $0
- Reporting owner signature
- /s/ James Foster
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
James Alexander Cunliffe Foster filed Form 3 for Virax Biolabs Group Ltd (VRAX) on 18 Mar 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0001988784
Primary reporting owner
Foster James Alexander Cunliffe
- Relationship
- Chief Executive Officer
- Address
- BIOCITY GLASGOW BO'NESS ROAD, NEWHOUSE LANARKSHIRE, MOTHERWELL LANARKSHIRE, UNITED KINGDOM
- Signature
- /s/ James Foster
- Signature date
- 18 Mar 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VRAX
holding
Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 287,987
- Date
- 18 Mar 2026
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VRAX
holding
Derivative
Stock Options (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 37,250
- Exercise price
- $50.00
- Footnotes
- F1
VRAX
holding
Derivative
Stock Options (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 40,000
- Exercise price
- $6.00
- Footnotes
- F2
VRAX
holding
Derivative
Stock Options (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 50,000
- Exercise price
- $0.6800
- Footnotes
- F3
VRAX
holding
Derivative
Stock Options (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 18,025
- Exercise price
- $0.8800
- Footnotes
- F4
VRAX
holding
Derivative
Stock Options (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 31,975
- Exercise price
- $0.8800
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
On July 20, 2022, the Company granted 37,250 stock options under the Company's 2023 Equity Incentive Plan. The stock options are fully vested.
Footnote F2
On April 18, 2023, the Company granted 40,000 stock options under the Company's 2023 Equity Incentive Plan. The options vest in equal thirds on April 18 of each of 2024, 2025, and 2026. The vested portions of such options will become exercisable upon vesting.
Footnote F3
On April 18, 2024, the Company granted 50,000 stock options under the Company's 2023 Equity Incentive Plan. The options vest in equal thirds on April 18 of each of 2025, 2026, and 2027. The vested portions of such options will become exercisable upon vesting.
Footnote F4
On April 8, 2025, the Company granted 18,025 stock options under the Company's 2024 Equity Incentive Plan. The options vest in equal thirds on April 8 of each of 2026, 2027, and 2028. The vested portions of such options will become exercisable upon vesting.
Footnote F5
On April 8, 2025, the Company granted 31,975 stock options under the Company's 2024 Equity Incentive Plan. The options vest in equal thirds on April 8 of each of 2026, 2027, and 2028. The vested portions of such options will become exercisable upon vesting.